Lipid-altering agents: the future.
Lipid-lowering is established as proven intervention to reduce atherosclerosis and its complications. This article summarises novel developments in the lipid-altering therapies under development. It also discusses other therapeutic targets, such as squalene synthase, microsomal transfer protein, acyl-cholesterol acyl transferase, cholesterol ester transfer protein, peroxosimal proliferator-activating receptors and lipoprotein (a), for which compounds have been developed and have at least reached trials in animal models. Lipid-altering drugs are likely to prove a fast-developing area for novel treatments, as possible synergies exist between new and established compounds for the treatment of atherosclerosis.
Wierzbicki
A S
AS
St Thomas' Hospital Campus, London, UK. anthony.wierzbicki@kcl.ac.uk
D001161:Arteriosclerosis / Q000517:prevention & control*; D001647:Bile Acids and Salts / Q000378:metabolism; D002352:Carrier Proteins / Q000037:antagonists & inhibitors; D053480:Cholesterol Ester Transfer Proteins; D008078:Cholesterol, LDL / Q000037:antagonists & inhibitors / Q000097:blood; D004268:DNA-Binding Proteins; D004798:Enzymes / Q000378:metabolism; D005544:Forecasting; D006023:Glycoproteins / Q000037:antagonists & inhibitors; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000517:prevention & control; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D007408:Intestinal Absorption / Q000187:drug effects; D050356:Lipid Metabolism; D000071518:Liver X Receptors; D057093:Orphan Nuclear Receptors; D016877:Oxidants / Q000378:metabolism; D047492:Peroxisome Proliferator-Activated Receptors / Q000037:antagonists & inhibitors; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists
D001647:Bile Acids and Salts; C506642:CETP protein, human; D002352:Carrier Proteins; D053480:Cholesterol Ester Transfer Proteins; D008078:Cholesterol, LDL; D004268:DNA-Binding Proteins; D004798:Enzymes; D006023:Glycoproteins; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D000071518:Liver X Receptors; D057093:Orphan Nuclear Receptors; D016877:Oxidants; D047492:Peroxisome Proliferator-Activated Receptors; D018160:Receptors, Cytoplasmic and Nuclear